Endo International plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Endo International plc
BBB National Programs’ appeals panel decision “includes factual and substantive inaccuracies, is not in accordance with NARB procedures, and misstates Colgate’s positions and arguments,” Colgate says. Panel upheld findings agreeing with P&G’s challenge of “removes 10 years of yellow stains” claim.
Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
‘Rebate walls’ report heads to US Congress, but Democratic commissioners suggest FTC’s typical approach to curtailing such practices is too time consuming.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- American Medical Systems, Inc.
- Anchen Pharmaceuticals, Inc.
- ASTORA Women's Health
- Auxilium Pharmaceuticals, Inc. (Actient Pharmaceuticals LLC
- Slate Pharmaceuticals)
- DAVA Pharmaceuticals, Inc
- Edict Pharmaceuticals Private Limited
- Endo Finance LLC
- Endo Health Solutions Inc.
- Endo Pharmaceuticals Holdings Inc.
- Endo Ventures Limited
- HealthTronics, Inc.
- Indevus Pharmaceuticals, Inc.
- JHP Pharmaceuticals, LLC
- Paladin Labs Inc. (Allon Therapeutics, Inc.
- Ativa Pharma S.A,
- Labopharm Inc.
- Triton Pharma, Inc.
- ViRexx Medical Corp.)
- Par Pharmaceutical Companies, Inc.
- Par Pharmaceutical, Inc.
- Penwest Pharmaceuticals Co.
- Qualitest Pharmaceuticals
- Strativa Pharmaceuticals
- Valera Pharmaceuticals